(Disclaimer: This article is for scientific use only, and the relevant information in the following content has been processed to protect patient privacy.) Abstract: A young male came to our hospital with progressively worsening nausea with abdominal distention for more than 1 month. After physical examination combined with gastroscopy, ultrasound, liver function and CT, he was diagnosed with pancreatic neuroendocrine tumor (grade G2), also known as pancreatic endocrine tumor (grade G2). The natural course of this disease does not exceed 3 months, but it is not drug-free. The patient has effectively prolonged the survival period and also improved the quality of life after active and effective targeted therapy and interventional embolization treatment. [Basic information] Male, 30 years old [Disease type] Pancreatic endocrine tumor (G2 level) [Hospital] The Second Hospital of Guangzhou Medical University [Consultation date] February 2021 [Treatment plan] Targeted therapy (sunitinib malate capsule + octreotide acetate microsphere for injection) + interventional embolization therapy [Treatment cycle] Long-term treatment with targeted drugs, liver interventional therapy after 12 courses, 2- to The patient’s condition was stable, prolonging survival and improving quality of life. A young man came to our hospital with progressively worsening dyspepsia with abdominal distension for more than 1 month. Physical examination revealed a bulging abdomen with positive ascites sign, considering a pneumoperitoneum. Liver function showed serum total bilirubin 35.5 μmol/L and direct bilirubin 13.0 μmol/L, suggesting liver function impairment, and the initial diagnosis was liver occupancy with a high possibility of liver metastatic cancer. After admission, he was given a CT scan + enhancement of the whole abdomen, which showed a caudal occupancy of the pancreatic body. Malignant lesions with liver, abdominal and retroperitoneal lymph node metastases and a large amount of peritoneal fluid were considered, and a percutaneous liver puncture biopsy suggested intrahepatic metastasis of pancreatic neuroendocrine tumor (grade G2), so the diagnosis of pancreatic neuroendocrine tumor (grade G2) with multiple metastases of liver, abdominal and retroperitoneal lymph nodes was confirmed. The patient was diagnosed with pancreatic neuroendocrine tumor (grade G2), combined with multiple metastases in the liver, abdominal cavity and retroperitoneal lymph nodes. After full communication with the patient and family, the patient was instructed to use sunitinib malate capsule + octreotide acetate microspheres for injection, a combination of targeted drugs. Interventional embolization of metastatic liver cancer was given from October 2021 to February 2022. The patient was treated with the combination of targeted drugs as well as interventional embolization to control the disease in a stable state, improve the quality of life and prolong the survival period. The patient was instructed to follow up once every 2-3 months to assess the disease control and adjust the treatment plan in time. The patient was reviewed every 2-3 months for chest and abdomen CT. On the first review, the peritoneal effusion basically disappeared, the number of liver metastases decreased, and the change of pancreatic tail occupancy was not obvious. On the second review, no obvious metastatic lesions were seen in retroperitoneal lymph nodes, and only 2 liver metastases remained. The third review was a whole-body PET/CT scan (after liver intervention in February 2022), which showed that the patient had only a few remaining active signals in the liver metastases, a few active signals were visible in the tail of the pancreas, and no metabolically increased signals were seen in the rest of the body. The efficacy rating was partial remission (PR). The patient was in good general condition, did not complain of abdominal distension, poor appetite and other discomforts, and was able to take care of himself. Overall, after the standardized targeted therapy and interventional embolization treatment, the patient’s survival was prolonged and the quality of life was improved. The patient was able to control and stabilize his disease through targeted therapy and interventional embolization treatment, which is very gratifying for the treating doctor. In addition, we remind patients to pay special attention to their diet during the treatment period, with a high-protein, low-fat diet, small and frequent meals, and avoid spicy and oily food. Attention should also be paid to regular rechecking of blood routine, liver and kidney function, blood and urine amylase and blood glucose as prescribed by the doctor to detect side effects and signs of disease progression early. Finally, it is recommended that family members should provide timely psychological help to patients to enhance their confidence in curing the disease, and seek help from psychologists if necessary. V. Personal insight Pancreatic neuroendocrine tumor is a rare type of pancreatic malignant tumor. Although some patients are of low malignancy, most of them have highly malignant potential, and many of them already have distant organ metastases at the time of initial diagnosis, therefore, it is extremely important to actively popularize cancer prevention and treatment knowledge and do a good job in secondary prevention. In addition, despite the poor treatment effect and prognosis of this disease, there is still great hope to prolong the survival and improve the quality of life by actively cooperating with doctors, as in the case of this patient, the disease was effectively controlled after combined treatment.